4D Molecular Therapeutics, Inc.

NasdaqGS:FDMT 주식 보고서

시가총액: US$346.7m

4D Molecular Therapeutics 미래 성장

Future 기준 확인 2/6

4D Molecular Therapeutics 의 수익은 연간 7.3% 감소할 것으로 예상되는 반면, 연간 수익은 70.5% 로 증가할 것으로 예상됩니다. 70.5% 연간. EPS는 연간 1.8% 만큼 쇠퇴할 것으로 예상됩니다. 자기자본이익률은 3년 후 -41.1% 로 예상됩니다.

주요 정보

-7.3%

수익 성장률

-1.8%

EPS 성장률

Biotechs 수익 성장28.5%
매출 성장률70.5%
향후 자기자본 수익률-41.1%
애널리스트 커버리지

Good

마지막 업데이트21 Nov 2024

최근 미래 성장 업데이트

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Just Reported And Analysts Have Been Cutting Their Estimates

Nov 12
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Just Reported And Analysts Have Been Cutting Their Estimates

Recent updates

Companies Like 4D Molecular Therapeutics (NASDAQ:FDMT) Are In A Position To Invest In Growth

Nov 24
Companies Like 4D Molecular Therapeutics (NASDAQ:FDMT) Are In A Position To Invest In Growth

4D Molecular Therapeutics: Market Expects Wet AMD Gene Therapy Failure - I'm Not So Sure

Oct 04

4D Molecular Therapeutics (NASDAQ:FDMT) Is In A Good Position To Deliver On Growth Plans

Aug 10
4D Molecular Therapeutics (NASDAQ:FDMT) Is In A Good Position To Deliver On Growth Plans

4D Molecular Therapeutics: R100 Vector Pushes Forward To Bring Q4 Of 2024 DME Data

Jul 19

4D Molecular Therapeutics: Catalysts With Pioneering Gene Therapy With Directed Evolution

Apr 29

4D Molecular Therapeutics Advances Wet AMD Treatment Paradigm

Feb 06

4D Molecular Therapeutics: Several Value Inflection Points To Watch In 2024

Jan 25

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Just Reported And Analysts Have Been Cutting Their Estimates

Nov 12
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Just Reported And Analysts Have Been Cutting Their Estimates

We're Not Very Worried About 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate

Nov 08
We're Not Very Worried About 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate

Here's Why We're Watching 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Situation

May 08
Here's Why We're Watching 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Situation

We're Keeping An Eye On 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate

Sep 29
We're Keeping An Eye On 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Rate

4D Molecular Therapeutics GAAP EPS of -$0.87, revenue of $0.16M

Aug 11

Here's Why We're Watching 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Situation

Jun 11
Here's Why We're Watching 4D Molecular Therapeutics' (NASDAQ:FDMT) Cash Burn Situation

수익 및 매출 성장 예측

NasdaqGS:FDMT - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜수익수익잉여 현금 흐름작전 현금평균 애널리스트 수
12/31/20262-204-209N/A4
12/31/20254-211-199-1188
12/31/20241-158-157-8810
9/30/20240-143-117-113N/A
6/30/202420-110-87-85N/A
3/31/202420-105-79-77N/A
12/31/202321-101-79-76N/A
9/30/202322-96-77-73N/A
6/30/20232-111-98-93N/A
3/31/20232-110-97-91N/A
12/31/20223-107-98-87N/A
9/30/20222-105-102-86N/A
6/30/20223-102-97-81N/A
3/31/202217-81-92-77N/A
12/31/202118-71-78-69N/A
9/30/202117-67-69-65N/A
6/30/202123-52-64-62N/A
3/31/202112-60-53-52N/A
12/31/202014-57-52-51N/A
9/30/202017-52-43-42N/A
6/30/202010-61-42-40N/A
3/31/20208-54-45-42N/A
12/31/20197-49-40-37N/A
9/30/20199-35-36-33N/A
6/30/201913-21-29-27N/A
3/31/201914-15-23-22N/A
12/31/201814-10-17-16N/A
12/31/20176-11N/A8N/A

애널리스트 미래 성장 예측

수입 대 저축률: FDMT 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: FDMT 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: FDMT 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: FDMT 의 수익(연간 70.5% ) US 시장( 8.9% 보다 빠르게 성장할 것으로 예상됩니다. 8.9% 연간).

고성장 수익: FDMT 의 수익(연간 70.5% )은 연간 20% 보다 빠르게 증가할 것으로 예상됩니다.


주당 순이익 성장 예측


미래 자기자본 수익률

미래 ROE: FDMT (는) 3년 내에 수익성이 없을 것으로 예상됩니다.


성장 기업 발견